Re: [Fwd: Immune Globulin Associated With Kidney Failure]

[Guest guest]

THANK YOU KIMBERLY FOR YOUR RESEARCH.. WE TRULY APPRECIATE ALL YOUR TIME AND

EFFORT... GOD BLESS AND TAKE CARE..

ANNETTE AND ALISSA

>

>Reply-To: PedPIDegroups

>To: Pediatric PID group <PedPIDonelist>

>Subject: [Fwd: Immune Globulin Associated With Kidney Failure]

>Date: Wed, 12 Apr 2000 00:35:26 -0500

>

>

>

>--- Immune Globulin Associated With Kidney Failure

>Date: Sat, 10 Jul 1999 20:58:52 EDT

>From: MATHERS313@...

>Reply-To: PedPIDonelist

>To: PedPIDonelist

>

>From: MATHERS313@...

>

>I found this article on Medscape.

>

>

>Immune Globulin Associated With Kidney Failure

>------------------------------------------------------------------------------

>--

>

>

>WESTPORT, Jun 28 (Reuters Health) - Immune globulin intravenous (IGIV)

>therapy was associated with 88 reported renal adverse events in the US

>between June 1985 and November 1998, according to a report from the US

>Centers for Disease Control and Prevention (CDC), in Atlanta, Georgia.

>

>While patients usually recovered in about 10 days, 13 patients died

>despite

>treatment, CDC officials report in the Morbidity and Mortality Weekly

>report

>for June 25. Most affected patients were median age 60, with a range

>from 3

>to 91 years, and had underlying conditions that increased their risk for

>renal events, such as diabetes or pre-existing kidney disease.

>

>The Food and Drug Administration (FDA) has approved IGIV for the

>treatment of

>six conditions, including bone marrow transplant patients older than 20

>years, children with HIV-1 infections, and those with certain types of

>leukemia. As many as 50 to 60 other conditions are also commonly treated

>with

>IGIV, including multiple sclerosis, adult HIV-infection, and other types

>of

>leukemia, the officials note.

>

>The CDC authors report that the incidence of adverse events with IGIV

>administration ranges from 1% to 15%. They recommend that all patients

>receiving IGIV be closely monitored for kidney problems during and after

>infusion, with particular attention paid to those over 65, those with

>complicating conditions, or those taking other drugs that may affect

>kidney

>function.

>

> " In addition, IGIV should be used judiciously and alternatives used when

>appropriate because of recent shortages, " according to the CDC report.

>

>MMWR 1999;48:518-521.

>

>

>

>------------------------------------------------------------------------------

>--

> Copyright © 1999 Reuters Ltd. All rights reserved. Republication or

>redistribution of Reuters content is expressly prohibited without the

>prior

>written consent of Reuters. Reuters shall not be liable for any errors

>or

>delays in the content, or for any actions taken in reliance thereon.

>RECOMMENDED LINKS

>SPECIALTY NEWS

>

>Internal Medicine

>

>

>

> 

>

>

>

>

>

>------------------------------------------------------------------------------

>--

>

>---------------------------

[Guest guest]

When you think about it IVIG is made from the protein portion of the blood,

so maybe it is related to rates of infusion of total # of grams, in some

neuro conditions these patients receive 200 grams monthly over 5 days.

That's an awful lot of protein for the kidneys to handle.

Take care.

lynne